@article{Peiyi2024,
  title = {CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.},
  author = {Xie Peiyi and Yu Mincheng and Zhang Bo and Yu Qiang and Zhao Yufei and Wu Mengyuan and Jin Lei and Yan Jiuliang and Zhou Binghai and Liu Shuang and Li Xiaoqiang and Zhou Chenhao and Zhu Xiaodong and Huang Cheng and Xu Yongfeng and Xiao Yongsheng and Zhou Jian and Fan Jia and Hung Mien-Chie and Ye Qinghai and Guo Lei and Li Hui},
  year = {2024},
  journal = {Journal of hepatology},
  doi = {10.1016/j.jhep.2024.02.009},
  pmid = {38403027},
  url = {https://pubmed.ncbi.nlm.nih.gov/38403027/},
  abstract = {BACKGROUND & AIMS: The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in resistance to anti-PD-1 therapy in HCC. METHODS: Gene expression in HCC specimens from 10 patients receiving anti-PD-1 therapy was identified by RNA-sequencing. A total of 404 HCC samples from tissu...},
}

@article{Razvan2018,
  title = {Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.},
  author = {Cristescu Razvan and Mogg Robin and Ayers Mark and Albright Andrew and Murphy Erin and Yearley Jennifer and Sher Xinwei and Liu Xiao Qiao and Lu Hongchao and Nebozhyn Michael and Zhang Chunsheng and Lunceford Jared K and Joe Andrew and Cheng Jonathan and Webber Andrea L and Ibrahim Nageatte and Plimack Elizabeth R and Ott Patrick A and Seiwert Tanguy Y and Ribas Antoni and McClanahan Terrill K and Tomassini Joanne E and Loboda Andrey and Kaufman David},
  year = {2018},
  journal = {Science (New York, N.Y.)},
  doi = {10.1126/science.aar3593},
  pmid = {30309915},
  url = {https://pubmed.ncbi.nlm.nih.gov/30309915/},
  abstract = {Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond. We report the evaluation of >300 patient samples across 22 tumor types from four KEYNOTE clinical trials. Tumor mutational burden (TMB) and a T cell-inflamed gene expression profile (GEP) exhibited joint predictive utility in identifying responders and nonresponders to the PD-1 antibody pembrolizum...},
}

@article{Ignacio2025,
  title = {Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.},
  author = {Melero Ignacio and de Miguel Luken Maria and de Velasco Guillermo and Garralda Elena and Martín-Liberal Juan and Joerger Markus and Alonso Guzman and Goebeler Maria-Elisabeth and Schuler Martin and König David and Dummer Reinhard and Reig Maria and Rodriguez Ruiz Maria-Esperanza and Calvo Emiliano and Esteban-Villarrubia Jorge and Oberoi Arjun and Sabat Paula and Soto-Castillo Juan José and Koster Kira-Lee and Saavedra Omar and Sayehli Cyrus and Gromke Tanja and Läubli Heinz and Ramelyte Egle and Fortuny Marta and Landa-Magdalena Ana and Moreno Irene and Torres-Jiménez Javier and Hernando-Calvo Alberto and Hess Dagmar and Racca Fabricio and Richly Heike and Schmitt Andreas M and Eggenschwiler Corinne and Sanduzzi-Zamparelli Marco and Vilalta-Lacarra Anna and Trojan Jörg and Koch Christine and Galle Peter R and Foerster Friedrich and Trajanoski Zlatko and Hackl Hubert and Gogolla Falk and Koll Florestan J and Wild Peter and Chun Felix Kyoung Hwan and Reis Henning and Lloyd Peter and Machacek Matthias and Gajewski Thomas F and Fridman Wolf H and Eggermont Alexander M M and Bargou Ralf and Schöniger Sandra and Rüschoff Josef and Tereshchenko Anastasiia and Zink Carina and da Silva Antonio and Lichtenegger Felix S and Akdemir Julia and Rüdiger Manfred and L'Huillier Phil and Dutta Aradhana and Haake Markus and Auckenthaler Alexandra and Gjorgjioska Ana and Rössler Bernhard and Hermann Frank and Liebig Mara and Reichhardt Daniela and Schuberth-Wagner Christine and Wischhusen Jörg and Fettes Petra and Auer Marlene and Klar Kathrin and Leo Eugen},
  year = {2025},
  journal = {Nature},
  doi = {10.1038/s41586-024-08305-z},
  pmid = {39663448},
  url = {https://pubmed.ncbi.nlm.nih.gov/39663448/},
  abstract = {Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment},
}

@article{Zhou2021,
  title = {TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.},
  author = {Jiang Zhou and Lim Seung-Oe and Yan Meisi and Hsu Jennifer L and Yao Jun and Wei Yongkun and Chang Shih-Shin and Yamaguchi Hirohito and Lee Heng-Huan and Ke Baozhen and Hsu Jung-Mao and Chan Li-Chuan and Hortobagyi Gabriel N and Yang Liuqing and Lin Chunru and Yu Dihua and Hung Mien-Chie},
  year = {2021},
  journal = {The Journal of clinical investigation},
  doi = {10.1172/JCI139434},
  pmid = {33855973},
  url = {https://pubmed.ncbi.nlm.nih.gov/33855973/},
  abstract = {Immune checkpoint blockade therapy has demonstrated promising clinical outcomes for multiple cancer types. However, the emergence of resistance as well as inadequate biomarkers for patient stratification have largely limited the clinical benefits. Here, we showed that tumors with high TYRO3 expression exhibited anti-programmed cell death protein 1/programmed death ligand 1 (anti-PD-1/PD-L1) resistance in a syngeneic mouse model and in patients who received anti-PD-1/PD-L1 therapy. Mechanisticall...},
}

@article{Man2021,
  title = {Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation.},
  author = {Yu Man and Peng Zhengxin and Qin Min and Liu Yang and Wang Jingning and Zhang Cai and Lin Jiaming and Dong Tianqi and Wang Lulu and Li Shasha and Yang Yongqin and Xu Shan and Guo Wencong and Zhang Xiao and Shi Mingjun and Peng Huiming and Luo Xianwen and Zhang Huixia and Zhang Li and Li Yan and Yang Xiang-Ping and Sun Shuguo},
  year = {2021},
  journal = {Molecular cell},
  doi = {10.1016/j.molcel.2021.01.010},
  pmid = {33606996},
  url = {https://pubmed.ncbi.nlm.nih.gov/33606996/},
  abstract = {Interferon-γ (IFN-γ)-mediated adaptive resistance is one major barrier to improving immunotherapy in solid tumors. However, the mechanisms are not completely understood. Here, we report that IFN-γ promotes nuclear translocation and phase separation of YAP after anti-PD-1 therapy in tumor cells. Hydrophobic interactions of the YAP coiled-coil domain mediate droplet initiation, and weak interactions of the intrinsically disordered region in the C terminus promote droplet formation. YAP partitions ...},
}

@article{Ming2022,
  title = {Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.},
  author = {Yi Ming and Zheng Xiaoli and Niu Mengke and Zhu Shuangli and Ge Hong and Wu Kongming},
  year = {2022},
  journal = {Molecular cancer},
  doi = {10.1186/s12943-021-01489-2},
  pmid = {35062949},
  url = {https://pubmed.ncbi.nlm.nih.gov/35062949/},
  abstract = {Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for various types of cancers. Nevertheless, the l...},
}

@article{Xueliang2024,
  title = {Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.},
  author = {Wang Xueliang and Fang Yi and Liang Wei and Wong Chi Chun and Qin Huanlong and Gao Yaohui and Liang Meinong and Song Lei and Zhang Yongxin and Fan Miao and Liu Chuanfa and Lau Harry Cheuk-Hay and Xu Lixia and Li Xiaoxing and Song Wu and Wang Junlin and Wang Na and Yang Tao and Mo Mengmiao and Zhang Xiang and Fang Jingyuan and Liao Bing and Sung Joseph J Y and Yu Jun},
  year = {2024},
  journal = {Cancer cell},
  doi = {10.1016/j.ccell.2024.08.019},
  pmid = {39303724},
  url = {https://pubmed.ncbi.nlm.nih.gov/39303724/},
  abstract = {Microsatellite stable (MSS) colorectal cancers (CRCs) are often resistant to anti-programmed death-1 (PD-1) therapy. Here, we show that a CRC pathogen, Fusobacterium nucleatum (Fn), paradoxically sensitizes MSS CRC to anti-PD-1. Fecal microbiota transplantation (FMT) from patients with Fn-high MSS CRC to germ-free mice bearing MSS CRC confers sensitivity to anti-PD-1 compared to FMT from Fn-low counterparts. Single Fn administration also potentiates anti-PD-1 efficacy in murine allografts and CD...},
}

@article{Chaojia2024,
  title = {Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8},
  author = {Chen Chaojia and Zhao Fangcheng and Peng Jiali and Zhao Di and Xu Liyun and Li Huayu and Ma Shuaiya and Peng Xueqi and Sheng Xue and Sun Yang and Wang Tixiao and Dong Haoqing and Ding Yuming and Wu Zhuanchang and Liang Xiaohong and Gao Lifen and Wang Hongyan and Ma Chunhong and Li Chunyang},
  year = {2024},
  journal = {Cell reports. Medicine},
  doi = {10.1016/j.xcrm.2024.101686},
  pmid = {39168104},
  url = {https://pubmed.ncbi.nlm.nih.gov/39168104/},
  abstract = {Resistance to PD-1 blockade in onco-immunotherapy greatly limits its clinical application. T cell immunoglobulin and mucin domain containing-3 (Tim-3), a promising immune checkpoint target, is cleaved by ADAM10/17 to produce its soluble form (sTim-3) in humans, potentially becoming involved in anti-PD-1 resistance. Herein, serum sTim-3 upregulation was observed in non-small cell lung cancer (NSCLC) and various digestive tumors. Notably, serum sTim-3 is further upregulated in non-responding patie...},
}

@article{Junnan2025,
  title = {Riplet promotes lipid metabolism changes associated with CD8 T cell exhaustion and anti-PD-1 resistance in hepatocellular carcinoma.},
  author = {Liang Junnan and Liao Jingyu and Chang Ruizhi and Jia Wenlong and Li Ganxun and Chen Zeyu and Wu Hang and Zhu Chang and Wen Jingyuan and Huang Qibo and Gao Han and Gui Zichen and Xu Weiqi and Liang Huifang and Liu Qiumeng and Xu Dafeng and Li Zifu and Xia Limin and Chen Xiaoping and Huang Zhao and Zhang Wanguang and Ding Zeyang and Zhang Bixiang},
  year = {2025},
  journal = {Science immunology},
  doi = {10.1126/sciimmunol.ado3485},
  pmid = {40577442},
  url = {https://pubmed.ncbi.nlm.nih.gov/40577442/},
  abstract = {The overall response rate to immunotherapy is modest in hepatocellular carcinoma (HCC), and immunotherapy resistance mechanisms are incompletely understood. We report that the E3 ubiquitin ligase },
}

@article{Xinyi2025,
  title = {Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.},
  author = {Guo Xinyi and Nie Hu and Zhang Wenwen and Li Jiesheng and Ge Jing and Xie Bowen and Hu Wenbo and Zhu Yicheng and Zhong Na and Zhang Xinmei and Zhao Xiaohong and Wang Xiaoshuang and Sun Qinli and Wei Kun and Chen Xiaoyuan and Ni Ling and Zhang Ting and Lu Shichun and Zhang Lei and Dong Chen},
  year = {2025},
  journal = {Cancer cell},
  doi = {10.1016/j.ccell.2025.01.001},
  pmid = {39889705},
  url = {https://pubmed.ncbi.nlm.nih.gov/39889705/},
  abstract = {Combination of anti-PD-1 with lenvatinib showed clinical efficacy in multiple cancers, yet the underlying immunological mechanisms are unclear. Here, we compared T cells in hepatocellular carcinoma (HCC) patients before and after combination treatment using single-cell transcriptomics and T cell receptor (scTCR) clonotype analyses. We found that tumor-infiltrating GZMK},
}

@article{Yunjae2024,
  title = {Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.},
  author = {Kim Yunjae and Kim Gihyeon and Kim Sujeong and Cho Beomki and Kim Sang-Yeob and Do Eun-Ju and Bae Dong-Jun and Kim Seungil and Kweon Mi-Na and Song Joon Seon and Park Sang Hyoung and Hwang Sung Wook and Kim Mi-Na and Kim Yeongmin and Min Kyungchan and Kim Sung-Han and Adams Mark D and Lee Charles and Park Hansoo and Park Sook Ryun},
  year = {2024},
  journal = {Cell host & microbe},
  doi = {10.1016/j.chom.2024.06.010},
  pmid = {39059396},
  url = {https://pubmed.ncbi.nlm.nih.gov/39059396/},
  abstract = {The gut microbiome significantly influences immune responses and the efficacy of immune checkpoint inhibitors. We conducted a clinical trial (NCT04264975) combining an anti-programmed death-1 (PD-1) inhibitor with fecal microbiota transplantation (FMT) from anti-PD-1 responder in 13 patients with anti-PD-1-refractory advanced solid cancers. FMT induced sustained microbiota changes and clinical benefits in 6 of 13 patients, with 1 partial response and 5 stable diseases, achieving an objective res...},
}

@article{Antoni2018,
  title = {Cancer immunotherapy using checkpoint blockade.},
  author = {Ribas Antoni and Wolchok Jedd D},
  year = {2018},
  journal = {Science (New York, N.Y.)},
  doi = {10.1126/science.aar4060},
  pmid = {29567705},
  url = {https://pubmed.ncbi.nlm.nih.gov/29567705/},
  abstract = {The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination. The main premise for inducing an immune response is the preexistence of antitumor T cells that were limit...},
}

@article{Hansen2024,
  title = {LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.},
  author = {Lin Hansen and Fu Liangmin and Zhou Xinwei and Yu Anze and Chen Yuhang and Liao Wuyuan and Shu Guannan and Zhang Lizhen and Tan Lei and Liang Hui and Wang Zhu and Deng Qiong and Wang Jieyan and Jin Meiyu and Chen Zhenhua and Wei Jinhuan and Cao Jiazheng and Chen Wei and Li Xiaofei and Li Pengju and Lu Jun and Luo Junhang},
  year = {2024},
  journal = {Cancer letters},
  doi = {10.1016/j.canlet.2024.216807},
  pmid = {38462037},
  url = {https://pubmed.ncbi.nlm.nih.gov/38462037/},
  abstract = {The tumour microenvironment (TME) drives bladder cancer (BLCA) progression. Targeting the TME has emerged as a promising strategy for BLCA treatment in recent years. Furthermore, checkpoint blockade therapies are only beneficial for a minority of patients with BLCA, and drug resistance is a barrier to achieving significant clinical effects of anti-programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) therapy. In this study, higher low-density lipoprotein receptor-relat...},
}

@article{Sanjeev2018,
  title = {TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.},
  author = {Mariathasan Sanjeev and Turley Shannon J and Nickles Dorothee and Castiglioni Alessandra and Yuen Kobe and Wang Yulei and Kadel Edward E and Koeppen Hartmut and Astarita Jillian L and Cubas Rafael and Jhunjhunwala Suchit and Banchereau Romain and Yang Yagai and Guan Yinghui and Chalouni Cecile and Ziai James and Şenbabaoğlu Yasin and Santoro Stephen and Sheinson Daniel and Hung Jeffrey and Giltnane Jennifer M and Pierce Andrew A and Mesh Kathryn and Lianoglou Steve and Riegler Johannes and Carano Richard A D and Eriksson Pontus and Höglund Mattias and Somarriba Loan and Halligan Daniel L and van der Heijden Michiel S and Loriot Yohann and Rosenberg Jonathan E and Fong Lawrence and Mellman Ira and Chen Daniel S and Green Marjorie and Derleth Christina and Fine Gregg D and Hegde Priti S and Bourgon Richard and Powles Thomas},
  year = {2018},
  journal = {Nature},
  doi = {10.1038/nature25501},
  pmid = {29443960},
  url = {https://pubmed.ncbi.nlm.nih.gov/29443960/},
  abstract = {Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer. However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here we examined tumours from a large cohort of patients with metastatic urothelial cancer wh...},
}

@article{N2019,
  title = {Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.},
  author = {Gide Tuba N and Quek Camelia and Menzies Alexander M and Tasker Annie T and Shang Ping and Holst Jeff and Madore Jason and Lim Su Yin and Velickovic Rebecca and Wongchenko Matthew and Yan Yibing and Lo Serigne and Carlino Matteo S and Guminski Alexander and Saw Robyn P M and Pang Angel and McGuire Helen M and Palendira Umaimainthan and Thompson John F and Rizos Helen and Silva Ines Pires da and Batten Marcel and Scolyer Richard A and Long Georgina V and Wilmott James S},
  year = {2019},
  journal = {Cancer cell},
  doi = {10.1016/j.ccell.2019.01.003},
  pmid = {30753825},
  url = {https://pubmed.ncbi.nlm.nih.gov/30753825/},
  abstract = {Cancer immunotherapies provide survival benefits in responding patients, but many patients fail to respond. Identifying the biology of treatment response and resistance are a priority to optimize drug selection and improve patient outcomes. We performed transcriptomic and immune profiling on 158 tumor biopsies from melanoma patients treated with anti-PD-1 monotherapy (n = 63) or combined anti-PD-1 and anti-CTLA-4 (n = 57). These data identified activated T cell signatures and T cell populations ...},
}

@article{Bo2022,
  title = {Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.},
  author = {Cheng Bo and Ding Kaikai and Chen Pengxiang and Ji Jianxiong and Luo Tao and Guo Xiaofan and Qiu Wei and Ma Chunhong and Meng Xue and Wang Jian and Yu Jinming and Liu Yuan},
  year = {2022},
  journal = {Cancer communications (London, England)},
  doi = {10.1002/cac2.12244},
  pmid = {34981670},
  url = {https://pubmed.ncbi.nlm.nih.gov/34981670/},
  abstract = {BACKGROUND: Second-generation programmed cell death-protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, such as bintrafusp alfa (M7824), SHR-1701, and YM101, have been developed to simultaneously block PD-1/PD-L1 and transforming growth factor-beta/transforming growth factor-beta receptor (TGF-β/TGF-βR). Consequently, it is necessary to identify predictive factors of lung cancer patients who are not only resistant to PD-1/PD-L1 inhibitors but also sensitive to bifunctional drugs. The pu...},
}

@article{Willy2016,
  title = {Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.},
  author = {Hugo Willy and Zaretsky Jesse M and Sun Lu and Song Chunying and Moreno Blanca Homet and Hu-Lieskovan Siwen and Berent-Maoz Beata and Pang Jia and Chmielowski Bartosz and Cherry Grace and Seja Elizabeth and Lomeli Shirley and Kong Xiangju and Kelley Mark C and Sosman Jeffrey A and Johnson Douglas B and Ribas Antoni and Lo Roger S},
  year = {2016},
  journal = {Cell},
  doi = {10.1016/j.cell.2016.02.065},
  pmid = {26997480},
  url = {https://pubmed.ncbi.nlm.nih.gov/26997480/},
  abstract = {PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identify factors that may influence innate sensitivity or resistance to anti-PD-1 therapy. We find that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2. Innately resistant tumors display a transcriptional sig...},
}

@article{Tongsen2025,
  title = {CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8},
  author = {Zheng Tongsen and Ding Chujie and Lai Shihui and Gao Yang and Lyu Cheng and Liu Caiqi and Shi Jiaqi and Li Xiaobo and Li Mingwei and Meng Hongxue and Li Mingqi and Liang Yingjian and Tai Sheng and Cheng Liang and Zhang Yan and Li Li and Han Peng and Sun Bin and Liu Te and Geng Feng and Hao Dapeng and Zhang Xue},
  year = {2025},
  journal = {Nature cell biology},
  doi = {10.1038/s41556-025-01753-3},
  pmid = {40925954},
  url = {https://pubmed.ncbi.nlm.nih.gov/40925954/},
  abstract = {The colon exhibits higher propensity for tumour development than ileum. However, the role of immune microenvironment differences in driving this disparity remains unclear. Here, by comparing paired ileum and colon samples from patients with colorectal cancer (CRC) and healthy donors, we identified ileum-enriched CD160},
}

@article{Wenhui2025,
  title = {MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1.},
  author = {Wang Wenhui and Chen Jiming and Wang Shibo and Sun Xinhai and Yang Jie and Yu Pengfei and Hu Guinv and Wang Jiang and Zhang Jing and Qiao Shuya and Wang Jianli and Zhang Gensheng and He Yuzhou and Feng Huajun and Cai Zhijian},
  year = {2025},
  journal = {Cell reports. Medicine},
  doi = {10.1016/j.xcrm.2024.101922},
  pmid = {39842432},
  url = {https://pubmed.ncbi.nlm.nih.gov/39842432/},
  abstract = {Anti-PD-1 therapy, effective in patients with various advanced tumors, still encounters the challenge of insensitivity in most patients. Here, we demonstrate that PD-L1 on tumor cell-derived extracellular vesicles (TEVs) is critical for anti-PD-1 therapy resistance. Reducing endogenous and transferring exogenous TEVs abrogates and induces anti-PD-1 therapy resistance, respectively. Notably, PD-L1 is sorted onto TEVs via the endosomal sorting complex required for transport after ubiquitination by...},
}

@article{Weishi2024,
  title = {Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.},
  author = {Cheng Weishi and Kang Kai and Zhao Ailin and Wu Yijun},
  year = {2024},
  journal = {Journal of hematology & oncology},
  doi = {10.1186/s13045-024-01581-2},
  pmid = {39068460},
  url = {https://pubmed.ncbi.nlm.nih.gov/39068460/},
  abstract = {Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) are some of the most common and promising targets in ICIs. Compared to ICI monotherapy, which occasionally demonstrates treatment resistance and limited efficacy, the dual blockade ...},
}
